EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Judit Riera-Arnau, Daniel Wang, Jordi Mollet, Lucía Bellas, Ricardo Boy, Carlos González-Cruz, Mònica Sabaté, Elena Ballarín, Vicenç García-Patos, Glòria Aparicio

Dermatology Reports · 23.06.2026

DOI: 10.4081/dr.2026.10247 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Dermatology Reports, online erschienen am 23.06.2026. Verfasst von Judit Riera-Arnau und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Ba…. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity impacts both the clinical management and therapeutic strategies for psoriasis. This study aims to describe the use of biological medicines in treating obese patients with moderate-to-severe psoriasis. We conducted a retrospective cohort study (2007-2022) of obese patients who initiated biological treatments for moderate-severe psoriasis. The primary outcome was the number of biological treatment lines required to achieve an optimal or adequate Psoriasis Area and Severity Index (PASI) score reduction. Secondary outcomes included the duration of biological use and reasons for discontinuation. We included 58 patients (mean age 50 years, body mass index [BMI] 35.9 kg/m2, psoriasis duration 16.5 years). Biological treatments enabled 77.6% (45) of patients to achieve an optimal response, and 87.9% (51) achieved an adequate response. The median time-to-response was 2-7 months, with the greatest improvements seen with adalimumab, etanercept, and ustekinumab. The primary reason for discontinuation was lack of effectiveness (50% of first-line treatments). This study suggests that systemic biologics are effective for obese psoriasis patients and emphasizes the need for close monitoring of reasons that lead to discontinuation. As biologics evolve, refining guidelines will be essential for optimizing psoriasis management in obese patients.

Schlagwörter

Stichwörter der Autor:innen

Psoriasisbiological therapydrug effectivenessobesitysevere psoriasis

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona; Department of Pharmacology, Therapeutics and Toxicology, Univ…
  • Department of Dermatology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut De Recerca, Vall d'Hebron Barcelona Campus Hospitalari, Barcelona.
  • Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona.

Zitieren

APA

Riera-Arnau, J., Wang, D., Mollet, J., Bellas, L., Boy, R., González-Cruz, C., Sabaté, M., Ballarín, E., García-Patos, V., & Aparicio, G. (2026). A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain. Dermatology Reports. https://doi.org/10.4081/dr.2026.10247

Vancouver

Riera-Arnau J, Wang D, Mollet J, Bellas L, Boy R, González-Cruz C, et al. A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain. Dermatology Reports. 2026. doi:10.4081/dr.2026.10247

BibTeX
@article{RieraArnau2026,
  author = {Riera-Arnau, Judit and Wang, Daniel and Mollet, Jordi and Bellas, Lucía and Boy, Ricardo and González-Cruz, Carlos and Sabaté, Mònica and Ballarín, Elena and García-Patos, Vicenç and Aparicio, Glòria},
  title = {A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain},
  journal = {Dermatology Reports},
  year = {2026},
  doi = {10.4081/dr.2026.10247}
}
Kostenlos starten →